Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

International trial aims to prevent Alzheimer’s in high-risk young adults

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

4 Feb 2025

Does COVID increase the risk of Alzheimer’s disease?

COVID-19, even in mild cases, is linked to changes in Alzheimer’s disease-related brain biomarkers comparable to four years of aging. This study raises concerns about long-term neurological risks and cognitive decline post-COVID.

2 Feb 2025

NIH-supported clinical trial to test experimental treatment for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

31 Jan 2025

Antibody therapy provides protection against severe H5N1 avian flu in monkeys

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of Pittsburgh and NIH Vaccine Research Center researchers report today in Science.

30 Jan 2025

University of Oklahoma researcher leads efforts to unravel mysteries of cognitive decline

An estimated 76,000 Oklahomans are living with Alzheimer's disease, a number that has surged by 13% in just five years. Yet, despite the increasing need for effective treatments, therapies for age-related dementia have largely failed to slow or halt the disease's progression.

29 Jan 2025

Bio-Rad launches TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits for antibody conjugation to StarBright Dyes

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the launch of its TrailBlazer™ Tag and TrailBlazer StarBright™ Dye Label Kits.

29 Jan 2025

Schrödinger selects Sapio Sciences to enhance in silico drug discovery from plasmid to structure

Sapio Sciences, the science-aware™ lab informatics platform, today announced that Schrödinger, a global leader in computational chemistry, has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules.

From Sapio Sciences 29 Jan 2025

Trilobio introduces whole-laboratory automation platform at SLAS2025

Trilobio, developer of whole lab automation solutions for advancing biology research, today introduced the first version of its comprehensive robotics, lab equipment and software platform at the Society for Laboratory Automation and Screening conference, SLAS2025, alongside pilot customer data, demonstrating the platform's abilities in advancing research workflows.

From Trilobio 28 Jan 2025

Groundbreaking research reveals key gut cells involved in food tolerance

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend from foe-destroying invaders while tolerating food and helpful bacteria.

28 Jan 2025

Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego.

27 Jan 2025

Updated guidelines for preventing and managing hepatitis B virus reactivation

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

27 Jan 2025

MIT breakthrough enables fast and uniform protein labeling in 3D tissues

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D tissues with unprecedented speed, uniformity, and versatility.

24 Jan 2025

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025